Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine

International Journal of Molecular Sciences

Volumn 15, Issue 3, 2014, Pages 3904-3925

  Jang, Shih Fan ^a,e   Liu, Wei Hsiu ^b,c   Song, Wen Shin ^a,d   Chiang, Kuan Lin ^a,e   Ma, Hsin I ^b,c   Kao, Chung Lan ^a,e   Chen, Ming Teh ^a,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Induced pluripotent stem cells; Nanoparticles; Neurodegenerative; Personalized medicine

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN [1-40]; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; DAUNORUBICIN; DJ 1 PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; KRUPPEL LIKE FACTOR 4; LEUCINE RICH REPEAT KINASE 2; LIPOSOME; MEPACRINE; MICRORNA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; PACLITAXEL; POLYGLACTIN; POLYLACTIDE; PRESENILIN; PROTEIN; SOLID LIPID NANOPARTICLE; STAGE SPECIFIC EMBRYO ANTIGEN 3; STAGE SPECIFIC EMBRYO ANTIGEN 4; TAU PROTEIN; TRA1 PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE; NANOPARTICLE; NEUROPROTECTIVE AGENT;

ADULT STEM CELL; ALZHEIMER DISEASE; BONE MARROW; CELL DIFFERENTIATION; CELL THERAPY; CYTOLOGY; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SCREENING; EMBRYONIC STEM CELL; FIBROBLAST; HEMATOPOIETIC STEM CELL; HUMAN; HUNTINGTON CHOREA; MESENCHYMAL STEM CELL; MONONUCLEAR STEM CELL; NANOMEDICINE; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; REVIEW; STEM CELL BIOLOGY; STEM CELL TRANSPLANTATION; STROMA CELL; STROMAL STEM CELL; SUBVENTRICULAR ZONE; CHEMISTRY; METABOLISM; NANOTECHNOLOGY; PATHOLOGY; PROCEDURES; TRENDS;

DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; INDUCED PLURIPOTENT STEM CELLS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 84896449933     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15033904     Document Type: Review

References (105)

1. De Vries, J. W.; Zhang, F.; Herrmann, A. Drug delivery systems based on nucleic acid nanostructures. J. Control. Release 2013, 172, 467-483.
2. Zhang, Z. Q.; Sun, Q. Q.; Zhong, J. L.; Yang, Q. H.; Li, H.; Cheng, D.; Liang, B. L.; Shuai, X. T. Magnetic resonance imaging-visible and pH-sensitive polymeric micelles for tumor targeted drug delivery. J. Biomed. Nanotechnol. 2014, 10, 216-226.
3. You, D. G.; Saravanakumar, G.; Son, S.; Han, H. S.; Heo, R.; Kim, K.; Kwon, I. C.; Lee, J. Y.; Park, J. H. Dextran sulfate-coated superparamagnetic iron oxide nanoparticles as a contrast agent for atherosclerosis imaging. Carbohydr. Polym. 2014, 101, 1225-1233.
4. O'Mahony, A. M.; Godinho, B.; Cryan, J. F.; O'Driscoll, C. M. Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: Formulating the solution. J. Pharm. Sci. 2013, 102, 3469-3484.
5. Zhang, C.; Wan, X.; Zheng, X.; Shao, X.; Liu, Q.; Zhang, Q.; Qian, Y. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. Biomaterials 2014, 35, 456-465.
6. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861-872.
7. Park, I. H.; Zhao, R.; West, J. A.; Yabuuchi, A.; Huo, H.; Ince, T. A.; Lerou, P. H.; Lensch, M. W.; Daley, G. Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451, 141-146.
8. Okita, K.; Ichisaka, T.; Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448, 313-317.
9. Yu, J.; Vodyanik, M. A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J. L.; Tian, S.; Nie, J.; Jonsdottir, G. A.; Ruotti, V.; Stewart, R.; et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318, 1917-1920.
10. Jia, F.; Liu, X.; Li, L.; Mallapragada, S.; Narasimhan, B.; Wang, Q. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J. Control. Release 2013, 172, 1020-1034.
11. Ernsting, M. J.; Murakami, M.; Roy, A.; Li, S. D. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control. Release 2013, 172, 782-794.
12. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60, 1615-1626.
13. Kumar, V.; Toffoli, G.; Rizzolio, F. Fluorescent carbon nanoparticles in medicine for cancer therapy. ACS Med. Chem. Lett. 2013, 4, 1012-1013.
14. Emerich, D. F.; Thanos, C. G. Targeted nanoparticle-based drug delivery and diagnosis. J. Drug Target. 2007, 15, 163-183.
15. Kumari, A.; Yadav, S. K.; Yadav, S. C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B 2010, 75, 1-18.
16. Li, S. D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5, 496-504.
17. Podduturi, V. P.; Magana, I. B.; O'Neala, D. P.; Derosa, P. A. Simulation of transport and extravasation of nanoparticles in tumors which exhibit enhanced permeability and retention effect. Comput. Method Programs Biomed. 2013, 112, 58-68.
18. Jain, R. K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7, 653-664.
19. Prabhu, S.; Ortega, M.; Ma, C. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. Int. J. Pharm. 2005, 301, 209-216.
20. Damge, C.; Reis, C. P.; Maincent, P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin. Drug Deliv. 2008, 5, 45-68.
21. Almeida, A. J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 2007, 59, 478-490.
22. Joshi, M. D.; Muller, R. H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71, 161-172.
23. Gallarate, M.; Trotta, M.; Battaglia, L.; Chirio, D. Preparation of solid lipid nanoparticles from W/O/W emulsions: Preliminary studies on insulin encapsulation. J. Microencapsul. 2009, 26, 394-402.
24. Muller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50, 161-177.
25. Martins, S.; Sarmento, B.; Ferreira, D. C.; Souto, E. B. Lipid-based colloidal carriers for peptide and protein delivery-Liposomes versus lipid nanoparticles. Int. J. Nanomed. 2007, 2, 595-607.
26. Sen, K.; Mandal, M. Second generation liposomal cancer therapeutics: Transition from laboratory to clinic. Int. J. Pharm. 2013, 448, 28-43.
27. Natarajan, J. V.; Ang, M.; Darwitan, A.; Chattopadhyay, S.; Wong, T. T.; Venkatraman, S. S. Nanomedicine for glaucoma: Liposomes provide sustained release of latanoprost in the eye. Int. J. Nanomed. 2012, 7, 123-131.
28. Lin, Y. Y.; Kao, H. W.; Li, J. J.; Hwang, J. J.; Tseng, Y. L.; Lin, W. J.; Lin, M. H.; Ting, G.; Wang, H. E. Tumor burden talks in cancer treatment with PEGylated liposomal drugs. PLoS One 2013, 8, e63078.
29. Zhang, L.; Yao, H. J.; Yu, Y.; Zhang, Y.; Li, R. J.; Ju, R. J.; Wang, X. X.; Sun, M. G.; Shi, J. F.; Lu, W. L. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012, 33, 565-582.
30. Lee, C. M.; Choi, Y. D.; Huh, E. J.; Lee, K. Y.; Song, H. C.; Sun, M. J.; Jeong, H. J.; Cho, C. S.; Bom, H. S. Polyethylene glycol (PEG) modified Tc-99m-HMPAO-liposome for improving blood circulation and biodistribution: The effect of the extent of PEGylation. Cancer Biother. Radiopharm. 2005, 20, 620-628.
31. Hatakeyama, H.; Akita, H.; Harashima, H. The polyethyleneglycol dilemma: Advantage and disadvantage of pegylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol. Pharm. Bull. 2013, 36, 892-899.
32. Joo, K. I.; Xiao, L.; Liu, S. L.; Liu, Y. R.; Lee, C. L.; Conti, P. S.; Wong, M. K.; Li, Z. B.; Wang, P. Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials 2013, 34, 3098-3109.
33. Alexis, F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly (lactic acid)-co-(glycolic acid). Polym. Int. 2005, 54, 36-46.
34. Danhier, F.; Ansorena, E.; Silva, J. M.; Coco, R.; le Breton, A.; Preat, V. PLGA-based nanoparticles: An overview of biomedical applications. J. Control. Release 2012, 161, 505-522.
35. Thote, A. J.; Chappell, J. T.; Gupta, R. B.; Kumar, R. Reduction in the initial-burst release by surface crosslinking of PLGA microparticles containing hydrophilic or hydrophobic drugs. Drug Dev. Ind. Pharm. 2005, 31, 43-57.
36. Musumeci, T.; Ventura, C. A.; Giannone, I.; Ruozi, B.; Montenegro, L.; Pignatello, R.; Puglisi, G. PLA/PLGA nanoparticles for sustained release of docetaxel. Int. J. Pharm. 2006, 325, 172-179.
37. Gupta, S.; Agarwal, A.; Gupta, N. K.; Saraogi, G.; Agrawal, H.; Agrawal, G. P. Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir. Drug Dev. Ind. Pharm. 2013, 39, 1866-1873.
38. Shubhra, Q. T. H.; Mackova, H.; Horak, D.; Fodor-Kardos, A.; Toth, J.; Gyenis, J.; Feczko, T. Encapsulation of human serum albumin in submicrometer magnetic poly(lactide-co-glycolide) particles as a model system for targeted drug delivery. E-Polymers 2013, 13, 310-318.
39. Adomako, M.; St-Hilaire, S.; Zheng, Y.; Eley, J.; Marcum, R. D.; Sealey, W.; Donahower, B. C.; LaPatra, S.; Sheridan, P. P. Oral DNA vaccination of rainbow trout, Oncorhynchus mykiss (Walbaum), against infectious haematopoietic necrosis virus using PLGA poly(D, L-Lactic-co-Glycolic Acid) nanoparticles. J. Fish Dis. 2012, 35, 203-214.
40. Kumar, A.; Wonganan, P.; Sandoval, M. A.; Li, X. R.; Zhu, S. J.; Cui, Z. R. Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles. J. Control. Release 2012, 163, 230-239.
41. Jianbo, G.; Xue, L.; Hongdan, Y.; Zhaohui, T.; Xing, T.; Chenchen, C.; Jinghua, X.; Hui, X. The anti-melanoma efficiency of the intratumoral injection of cucurbitacin-loaded sustained-release carriers: A PLGA particle system. J. Pharm. Sci. 2013, 102, 2550-2563.
42. Schleich, N.; Sibret, P.; Danhier, P.; Ucakar, B.; Laurent, S.; Muller, R. N.; Jerome, C.; Gallez, B.; Preat, V.; Danhier, F. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int. J. Pharm. 2013, 447, 94-101.
43. Zolnik, B. S.; Burgess, D. J. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J. Control. Release 2008, 127, 137-145.
44. Bae, S. E.; Son, J. S.; Park, K.; Han, D. K. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. J. Control. Release 2009, 133, 37-43.
45. Chattopadhyay, S.; Ehrman, S. H.; Venkataraman, C. Size distribution and dye release properties of submicron liposome aerosols. Powder Technol. 2013, 246, 530-538.
46. Das, M. K.; Husain, K.; Pathak, Y. Brain targeted delivery of curcumin using P80-PEG-coated poly(lactide-co-glycolide) nanoparticles. Asian J. Chem. 2013, 25, S297-S301.
47. Tsai, Y. M.; Jan, W. C.; Chien, C. F.; Lee, W. C.; Lin, L. C.; Tsai, T. H. Optimised nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats. Food Chem. 2011, 127, 918-925.
48. Glasker, S.; Li, J.; Xia, J. B.; Okamoto, H.; Zeng, W. F.; Lonser, R. R.; Zhuang, Z. P.; Oldfield, E. H.; Vortmeyer, A. O. Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res. 2006, 66, 4167-4172.
49. Pelosi, E.; Valtieri, M.; Coppola, S.; Botta, R.; Gabbianelli, M.; Lulli, V.; Marziali, G.; Masella, B.; Muller, R.; Sgadari, C.; et al. Identification of the hemangioblast in postnatal life. Blood 2002, 100, 3203-3208.
50. Brunstein, C. G. Umbilical Cord Blood Transplantation for the treatment of hematologic malignancies. Cancer Control 2011, 18, 222-236.
51. Gage, F. H. Mammalian neural stem cells. Science 2000, 287, 1433-1438.
52. Goldman, S. Stem and progenitor cell-based therapy of the human central nervous system. Nat. Biotechnol. 2005, 23, 862-871.
53. Alvarez-Buylla, A.; Lim, D. A. For the long run: Maintaining germinal niches in the adult brain. Neuron 2004, 41, 683-686.
54. Ma, D. K.; Bonaguidi, M. A.; Ming, G. L.; Song, H. J. Adult neural stem cells in the mammalian central nervous system. Cell Res. 2009, 19, 672-682.
55. Ma, D. K.; Ming, G. L.; Song, H. J. Glial influences on neural stem cell development: Cellular niches for adult neurogenesis. Curr. Opin. Neurobiol. 2005, 15, 514-520.
56. Sun, Y. Myocardial repair/remodelling following infarction: Roles of local factors. Cardiovasc. Res. 2009, 81, 482-490.
57. Evans, M. J.; Kaufman, M. H. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292, 154-156.
58. Martin, G. R. Isolation of a pluripotent cell-line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem-cells. Proc. Natl. Acad. Sci. USA 1981, 78, 7634-7638.
59. Thomson, J. A.; Itskovitz-Eldor, J.; Shapiro, S. S.; Waknitz, M. A.; Swiergiel, J. J.; Marshall, V. S.; Jones, J. M. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282, 1145-1147.
60. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126, 663-676.
61. Stadtfeld, M.; Hochedlinger, K. Induced pluripotency: History, mechanisms, and applications. Genes Dev. 2010, 24, 2239-2263.
62. Hanna, J. H.; Saha, K.; Jaenisch, R. Pluripotency and cellular reprogramming: Facts, hypotheses, unresolved issues. Cell 2010, 143, 508-525.
63. Mikkelsen, T. S.; Hanna, J.; Zhang, X. L.; Ku, M. C.; Wernig, M.; Schorderet, P.; Bernstein, B. E.; Jaenisch, R.; Lander, E. S.; Meissner, A. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008, 454, 49-55.
64. Feng, B.; Ng, J. H.; Heng, J. C. D.; Ng, H. H. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009, 4, 301-312.
65. Xia, C.; Wenwen, D.; Qingtong, R. Q.; Li, Y. J.; Yang, Y.; Cao, Y.; Gao, X.; Xu, X.; Yu, J. Non-viral co-delivery of the four yamanaka factors for generation of human induced pluripotent stem cells via calcium phosphate nanocomposite particles. Adv. Funct. Mater. 2013, 23, 5403-5411.
66. Sohn, Y. D.; Somasuntharam, I.; Che, P. L.; Jayswal, R.; Murthy, N.; Davisa, M. E.; Yoon, Y. S. Induction of pluripotency in bone marrow mononuclear cells via polyketal nanoparticle-mediated delivery of mature microRNAs. Biomaterials 2013, 34, 4235-4241.
67. Mattis, V. B.; Svendsen, C. N. Induced pluripotent stem cells: A new revolution for clinical neurology? Lancet Neurol. 2011, 10, 383-394.
68. Kim, D. S.; Lee, J. S.; Leem, J. W.; Huh, Y. J.; Kim, J. Y.; Kim, H. S.; Park, I. H.; Daley, G. Q.; Hwang, D. Y.; Kim, D. W. Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity. Stem Cell Rev. Rep. 2010, 6, 270-281.
69. Ferrante, R. J. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim. Biophys. Acta 2009, 1792, 506-520.
70. Trettel, F.; Rigamonti, D.; Hilditch-Maguire, P.; Wheeler, V. C.; Sharp, A. H.; Persichetti, F.; Cattaneo, E.; MacDonald, M. E. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 2000, 9, 2799-2809.
71. Ross, C. A.; Tabrizi, S. J. Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10, 83-98.
72. Cimini, A.; Gentile, R.; Angelucci, F.; Benedetti, E.; Pitari, G.; Giordano, A.; Ippoliti, R. Neuroprotective effects of prxi over-expression in an in vitro human Alzheimer's disease model. J. Cell. Biochem. 2013, 114, 708-715.
73. HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show cag-repeat-expansion-associated phenotypes. Cell Stem Cell 2012, 11, 264-278.
74. Duyao, M.; Ambrose, C.; Myers, R.; Novelletto, A.; Persichetti, F.; Frontali, M.; Folstein, S.; Ross, C.; Franz, M.; Abbott, M.; et al. Trinucleotide repeat length instability and age-of-onset in Huntingtons' disease. Nat. Genet. 1993, 4, 387-392.
75. Langbehn, D. R.; Hayden, M. R.; Paulsen, J. S.; Huntingto, P.-H. I. CAG-repeat length and the age of onset in huntington disease (HD): A review and validation study of statistical approaches. Am. J. Med. Genet. B 2010, 153B, 397-408.
76. Park, I. H.; Arora, N.; Huo, H.; Maherali, N.; Ahfeldt, T.; Shimamura, A.; Lensch, M. W.; Cowan, C.; Hochedlinger, K.; Daley, G. Q. Disease-specific induced pluripotent stem cells. Cell 2008, 134, 877-886.
77. Zhang, N.; An, M. C.; Montoro, D.; Ellerby, L. M. Characterization of human huntington's disease cell model from induced pluripotent stem cells. PLoS Curr. 2010, doi: 10. 1371/currents. RRN1193.
78. Kaye, J. A.; Finkbeiner, S. Modeling Huntington's disease with induced pluripotent stem cells. Mol. Cell. Neurosci. 2013, 56, 50-64.
79. Foltynie, T.; Brayne, C. E. G.; Robbins, T. W.; Barker, R. A. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004, 127, 550-560.
80. Zuo, L.; Motherwell, M. S. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene 2013, 532, 18-23.
81. Mori, F.; Nishie, M.; Kakita, A.; Yoshimoto, M.; Takahashi, H.; Wakabayashi, K. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J. Neuropathol. Exp. Neurol. 2006, 65, 808-815.
82. Dawson, T. M. Unraveling the role of defective genes in Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13, S248-S249.
83. De Lau, L. M. L.; Breteler, M. M. B. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5, 525-535.
84. Soldner, F.; Hockemeyer, D.; Beard, C.; Gao, Q.; Bell, G. W.; Cook, E. G.; Hargus, G.; Blak, A.; Cooper, O.; Mitalipova, M.; et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136, 964-977.
85. Von Kalle, C.; Fehse, B.; Layh-Schmitt, G.; Schmidt, M.; Kelly, P.; Baum, C. Stem cell clonality and genotoxicity in hematopoietic cells: Gene activation side effects should be avoidable. Semin. Hematol. 2004, 41, 303-318.
86. Soldner, F.; Laganiere, J.; Cheng, A. W.; Hockemeyer, D.; Gao, Q.; Alagappan, R.; Khurana, V.; Golbe, L. I.; Myers, R. H.; Lindquist, S.; et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutation. Cell 2011, 146, 318-331.
87. Ballatore, C.; Lee, V. M. Y.; Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8, 663-672.
88. Hardy, J.; Selkoe, D. J. Medicine-The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
89. Israel, M. A.; Yuan, S. H.; Bardy, C.; Reyna, S. M.; Mu, Y. L.; Herrera, C.; Hefferan, M. P.; van Gorp, S.; Nazor, K. L.; Boscolo, F. S.; et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012, 482, 216-220.
90. Zhao, T. B.; Zhang, Z. N.; Rong, Z. L.; Xu, Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474, 212-215.
91. Barrilleaux, B.; Knoepfler, P. S. Inducing iPSCs to escape the dish. Cell Stem Cell 2011, 9, 103-111.
92. Wu, Y.-L.; Pandian, G. N.; Ding, Y.-P.; Zhang, W.; Tanaka, Y.; Sugiyama, H. Clinical grade iPS cells: Need for versatile small molecules and optimal cell sources. Chem. Biol. 2013, 20, 1311-1322.
93. Pandian, G. N.; Nakano, Y.; Sato, S.; Morinaga, H.; Bando, T.; Nagase, H.; Sugiyama, H. A synthetic small molecule for rapid induction of multiple pluripotency genes in mouse embryonic fibroblasts. Sci. Rep. 2012, 2, doi: 10. 1038/srep00544.
94. Hou, P. P.; Li, Y. Q.; Zhang, X.; Liu, C.; Guan, J. Y.; Li, H. G.; Zhao, T.; Ye, J. Q.; Yang, W. F.; Liu, K.; et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013, 341, 651-654.
95. Saha, K.; Jaenisch, R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 2009, 5, 584-595.
96. Dimos, J. T.; Rodolfa, K. T.; Niakan, K. K.; Weisenthal, L. M.; Mitsumoto, H.; Chung, W.; Croft, G. F.; Saphier, G.; Leibel, R.; Goland, R.; et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321, 1218-1221.
97. Ebert, A. D.; Yu, J. Y.; Rose, F. F.; Mattis, V. B.; Lorson, C. L.; Thomson, J. A.; Svendsen, C. N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457, 277-280.
98. McLaren, M. J. Kinetics of rod outer segment phagocytosis by cultured retinal pigment epithelial cells-Relationship to cell morphology. Investig. Ophthalmol. Visual Sci. 1996, 37, 1213-1224.
99. Osakada, F.; Jin, Z. B.; Hirami, Y.; Ikeda, H.; Danjyo, T.; Watanabe, K.; Sasai, Y.; Takahashi, M. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J. Cell Sci. 2009, 122, 3169-3179.
100. Singh, R.; Shen, W.; Kuai, D.; Martin, J. M.; Guo, X. R.; Smith, M. A.; Perez, E. T.; Phillips, M. J.; Simonett, J. M.; Wallace, K. A.; et al. iPS cell modeling of Best disease: Insights into the pathophysiology of an inherited macular degeneration. Hum. Mol. Genet. 2013, 22, 593-607.
101. Leek, J. T.; Peng, R. D.; Anderson, R. R. Keep a way open for tailored treatments. Nature 2012, 484, 318-318.
102. Jiang, T. F.; Zhang, Y. J.; Zhou, H. Y.; Wang, H. M.; Tian, L. P.; Liu, J.; Ding, J. Q.; Chen, S. D. Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. J. Neuroimmune Pharmacol. 2013, 8, 356-369.
103. Romano, G.; Morales, F.; Marino, I. R.; Giordano, A. A commentary on iPS cells: Potential applications in autologous transplantation, study of illnesses and drug screening. J. Cell. Physiol. 2014, 229, 148-152.
104. Pagliari, F.; Mandoli, C.; Forte, G.; Magnani, E.; Pagliari, S.; Nardone, G.; Licoccia, S.; Minieri, M.; di Nardo, P.; Traversa, E. Cerium oxide nanoparticles protect cardiac progenitor cells from oxidative stress. ACS Nano 2012, 6, 3767-3775.
105. Chen, W.; Tsai, P. H.; Hung, Y.; Chiou, S. H.; Mou, C. Y. Nonviral cell labeling and differentiation agent for induced pluripotent stem cells based on mesoporous silica nanoparticles. ACS Nano 2013, 7, 8423-8440.